Current Report · Items 2.02, 7.01, 9.01 · 8-K
LifeMD, Inc.
LFMDNASDAQEQUITYCurrent
Results of Operations and Financial Condition · Regulation FD Disclosure
Item 2.02. Results of Operations and Financial Condition. On May 6, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Filed May 6, 2026Accepted May 6, 2026, 5:04 PM EDTCIK 948320Accession 0001493152-26-021520
Company context
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men’s and women’s health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.
Current securities
Disclosure sections
Items 2.02, 7.01, 9.01Select an item to read the extracted section. The as-filed document remains the primary evidence.
Item 2.02Item 2.02 - Results of Operations
Item
2.02. Results of Operations and Financial Condition.
On
May 6, 2026, LifeMD, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended
March 31, 2026. A copy of the press release is furnished herewith as Exhibit 99.1.
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01. Regulation FD Disclosure.
The
Company hereby furnishes an investor presentation (the “Presentation”), which it expects to use in whole or in part, and
possibly with modifications, in connection with presentations to investors, analysts and others commencing on May 6, 2026. The Presentation
is furnished herewith as Exhibit 99.2 and may also be found on the Company’s website at https://lifemd.com.
By
filing this Current Report on Form 8-K and furnishing the information contained herein, the Company makes no admission as to the materiality
of any information in this Current Report that is required to be disclosed solely by reason of Regulation FD. The information contained
in the Presentation is summary information that is intended to be considered in the context of the Company’s Securities and Exchange
Commission (“SEC”) filings and other public announcements that the Company may make, by press release or otherwise, from
time to time. The Company undertakes no duty or obligation to publicly update or revise the information contained in this report, although
it may do so from time to time as its management believes is warranted. Any such updating may be made through the filing of other reports
or documents with the SEC, through press releases or through other public disclosure.
The
information in this Current Report on Form 8-K (including Exhibits attached hereto) shall not be deemed “filed” for purposes
of Section 18 of the Securities Exchange Act of 1934, nor shall it be deemed incorporated by reference in any filing under the Securities
Act of 1933 or the Securities Exchange Act of 1934, except as shall be expressly set forth by specific reference in such filing.
Cautionary
Note Regarding Forward-Looking Statements
This
Current Report on Form 8-K includes information that may constitute forward-looking statements. These forward-looking statements are
based on the Company’s current beliefs, assumptions, and expectations regarding future events, which in turn are based on information
currently available to the Company. By their nature, forward-looking statements address matters that are subject to risks and uncertainties.
Forward-looking statements include, without limitation, statements relating to projected industry growth rates, the Company’s current
growth rates and the Company’s present and future cash flow position. A variety of factors could cause actual events and results,
as well as the Company’s expectations, to differ materially from those expressed in or contemplated by the forward-looking statements.
Risk factors affecting the Company are discussed in detail in the Company’s filings with the SEC. The Company undertakes no obligation
to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except
to the extent required by applicable securities laws.
Filed exhibits (2)
EX-99.1 (by filename) ex99-1.htmEX-99.1
2
ex99-1.htm
EX-99.1
Exhibit
99.1
LifeMD
Reports First Quarter 2026 Results
Gross
margin increased approximately 420 basis points to 88%, versus the first quarter of 2025,
reflecting favorable revenue mix and lower fulfillment costs.
Record
GLP-1 patient sign-ups, with weight management new-patient revenues growing approximately
120% versus the fourth quarter of 2025.
657%
quarter-over-quarter growth in Women’s Health patient signups with approximately 70%
reduction in customer acquisitions costs with scalable unit economics achieved.
──────────────────────────────────────────────────────────────────────────────────────────────
First
quarter 2026 revenue of $50.2 million and adjusted EBITDA loss of $4.5 million, above and
in line, respectively, with the Company’s guidance.
Exited
the quarter with $34.5 million of cash and no debt; affirming full year 2026 guidance for
revenue of $220 million to $230 million and adjusted EBITDA of $12 million to $17 million.
Conference
call begins at 4:30 p.m. Eastern time today
NEW
YORK, May 6, 2026 - LifeMD, Inc. (Nasdaq: LFMD), a leading platform for virtual primary care services, today reported
fina…
Open exhibit ↗EX-99.2 (by filename) ex99-2.htmEX-99.2
Open exhibit ↗